Nippon Shinyaku and Atsena Therapeutics form exclusive partnership for ATSN-101 in the U.S. and Japan
Nippon Shinyaku and Atsena Therapeutics form exclusive partnership for ATSN-101 in the U.S. and Japan
11/13/24, 6:51 AM
Location
durhamIndustry
pharmaceutical
biotechnology
Type
partnership
Nippon Shinyaku and Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the U.S. and for the development and commercialization of ATSN-101 in Japan. Under the agreement, Nippon Shinyaku will receive exclusive commercial rights in the U.S. and Japan, while Atsena will retain commercial rights in the rest of the world